Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03398655 · ClinicalTrials.gov registry record · Phase 3
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
A Phase 3 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT03398655 is a Phase 3 study that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 408 participants.
The verdict
NCT03398655, a Phase 3 study, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Interventions
- DRUG VB-111 + Paclitaxel
- DRUG Placebo + Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2022-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03398655
The ClinicalTrials.gov registry entry for NCT03398655 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VB-111 + Paclitaxel is the first listed.
NCT03398655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03398655 about?
NCT03398655 is a clinical study titled "A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)". The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
What is the current status of trial NCT03398655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2017-12-19. Estimated completion is 2022-07-19.
What interventions are being tested in trial NCT03398655?
The interventions under investigation include: VB-111 + Paclitaxel (DRUG), Placebo + Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03398655?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.